Impact of Topical Nepafenac on Macular Thickness after Phacoemulsification with Intraocular Lens Implantation in Patients without Diabetic Retinopathy

  • Arooj Amjad
  • Muhammad Shaheer COAVS/KEMU, Lahore
  • Hassan Tariq
  • Ammarah Rasheed
Keywords: Phacoemulsification, Optical Coherence Tomography, Non-steroidal Anti-Inflammatory Agents

Abstract

Objective: To study the effect of post-operative Non-Steroidal Anti-inflammatory (NSAID) eye drops on macular thickness in patients without diabetic retinopathy measured by Optical Coherence Tomography (OCT).
Study Design: Quasi-experimental study.
Place & Duration of the Study: Ophthalmology Department/ Lahore General Hospital, Lahore from 15-01-2019 to 31-12-2021.
Materials and Methods: Diabetic patients without retinopathy who required cataract surgery for visual rehabilitation were included in the study. They were then divided into two groups. Group A included patients who received routine steroid+antibiotic post-operative drops while Group B comprised of patients who received nepafenac (0.1%) eye drops eight hourly in addition to routine post-operative eye drops. All patients underwent standard phacoemulsification and intraocular lens implantation followed by the use of NSAID eye drops for a month. OCT measurements were done pre-operatively, 7 and 28 days post-operatively.
Results: Comparison of central macular thickness between groups was significant at (Pre & 7-day post-op) and insignificant at (7th day & 28th day post-op) and (Pre & 28th day post-op) i.e. 0.043, 0.834, and 0.084 respectively. However, a difference in mean central macular thickness was significant at all follow-up periods i.e.0.003, 0.006, and 0.000.
Conclusion: Post-operative NSAID in diabetic patients without retinopathy leads to a significant decrease in macular thickness as compared to controls after cataract surgery.

References

1-Lundstrom M, Goh PP, Henry Y, Salowi MA, Barry P, Manning S et al. The Changing
Pattern of Cataract Surgery Indications. Ophthalmology. 2015;122(1):31-38.

2-Gogate P, Jaggernath JB, Deshpande S, Naidoo K. Meta-analysis to Compare the Safety
and Efficacy of Manual Small Incision Cataract Surgery and Phacoemulsification. Middle
East Afr J Ophthalmmol. 2015;22(3):362-369.

3-Bajpayee N, Tidake PK, Palsodkar PM. Comparitive study of visual acuity and astigmatism
determination between small incision cataract surgery and phacoemulsification by corneal
topography. Int J Curr Res Rev. 2020;22(12):65-68.

4-Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS
J. 2008;10:229–241.

5- Deka A. Comparative study of topical steroids vs nonsteroidal anti-inflammatory drugs to
control postcataract surgery inflammation. J Cat & Ref Surg. 2020;46(10):1397-1401.
doi: 10.1097/j.jcrs.0000000000000291

6-Kee TL, Graff G, Spellman JM, Yanni JM. Nepafenac, A unique Nonsteroidal prodrug with
potential utility in the treatment of trauma induced ocular inflammation: II. In vivo
bioactivation and permeation of external ocular barriers. Inflammation. 2000;24(4):371-
384.

7- Aaronson A, Achiron A, Tuuminen R. Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac. J Clin Med. 2020, 9(9), 3034; https://doi.org/10.3390/jcm9093034

8-Popovic MM, Muni RH, Nichani P, Kertes PJ. Topical Nonsteroidal Anti-inflammatory Drugs for
Pain Resulting from Intravitreal Injections: A Meta-Analysis. Ophthalmol Ret. 2020;4(5):461-
470. https://doi.org/10.1016/j.oret.2020.01.024

9-Mathys KC, Cohen KS. Impact of nepafenac 0.1% on macular thickness and post
operative visual acuity after cataract surgery in patients at low risk for cystoid macular
edema. Eye. 2010;24:90-96.

10- Tzelikis PF, Morato CS, Neves NT, Hida WT, Alves MR. Intraindividual comparison of
nepafenac 0.3% for the prevention of macular edema after phacoemulsification. J Cat &
Ref Surg. 2018;44(4):440-446.

11-Singh R, Alprem L, Jaffe GJ, Lehmann RP, Lim j et al. Evaluation of nepafenac in prevention of
macular edema following cataract surgery in patients with diabetic retinopathy. Clin
Ophthalmol. 2012; 6: 1259–1269. doi: 10.2147/OPTH.S31902.

12- Stock RA, Galvan DK, Godoy R, Bonamigo EL. Comparison of macular thickness by optical
coherence tomography measurements after uneventful phacoemulsification using ketorolac
trimethamine, nepafenac, vs a control group, preoperatively and postoperatively. Clin
Ophthalmol. 2018;12:607-611.

13- Ellakwa AF, Badaway NM, Al Said MA. Evaluation of nepafenac eye drops in prevention of
macular edema following cataract surgery. Menoufia Med J. 2020;33(2):604-610.

14- Singh RP, Lehmann R, Martel J, Jong K, Pollack A, Tsorbatzoglou A et al. Nepafenac 0.3%
after cataract surgery in patients with diabetic retinopathy: Results of 2 randomized phase
3 studies. Ophthalmology. 2017;124(6):776-785.
https://doi.org/10.1016/j.ophtha.2017.01.036

15- Pollack A, Staurenghi G, Sager D, Mukesh B, Singh RP. Prospective randomized clinical trial
to evaluate the safety and efficacy of 0.1% treatment for the prevention of macular edema
associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol.
2017;101:427. http://dx.doi.org/10.1136/bjophthalmol-2016-308617

16- El Gharbway SA, Darwish EA, Abu Eleinen KG, Osman MH. Efficacy of addition of nepafenac
0.1% to steroid eye drops in prevention of post phaco macular edema in high risk eyes. Eur J
Ophthalmol. 2019;29(4): https://doi.org/10.1177/1120672118799626

17- Daani R, Viljanen A, Aaronson A, Tuuminen R. Pre-operative anti-inflammatory treatment of
diabetic patients does not improve recovery from cataract surgery when post operatively
treated with a combination of prednisolone acetate and nepafenac. Act Ophthalmol.
2019;97:589-595. https://doi.org/10.1111/aos.14018

18- Campa C, Salsini, Perri P. Comparison of the efficacy of dexamethasone, nepafenac, and
bromofenac for preventing pseudophakic cystoid macular edema: an open-label,
prospective, randomized controlled trial. Curr Eye Res. 2018;43(3):362-367.
https://doi.org/10.1080/02713683.2017.1396615

19- Sahin AK, Kukner AS, Ulas F, Dogan U. Effect of nepafenac 0.1% on retinal thickness after
cataract surgery in patient without risk factors for cystoid macular edema. Int J Ophthalmol.
2020;13(12):1901-1907. DOI:10.18240/ijo.2020.12.09

20- Sarfraz MH, Haq RI, Mehboob MA. Effect of topical nepafenac inn prevention of macular
edema after cataract surgery in patients with non-proliferative diabetic retinopathy. Pak J
Med Sci. 2017; 33(1): 210–214. doi: 10.12669/pjms.331.11644.
Published
2022-06-30
How to Cite
1.
Amjad A, Shaheer M, Tariq H, Rasheed A. Impact of Topical Nepafenac on Macular Thickness after Phacoemulsification with Intraocular Lens Implantation in Patients without Diabetic Retinopathy. JRMC [Internet]. 30Jun.2022 [cited 24Sep.2022];26(2):301-5. Available from: http://www.journalrmc.com/index.php/JRMC/article/view/1877
Section
Articles